Video content above is prompted by the following: Discuss the use of CALGB 10403 in AYA ALL. (Stock W et al. Blood 2019) Might you have considered a different regimen for this patient? Please comment on the key efficacy outcomes. What were some AEs reported with this regimen? How might you mitigate them?